Naphthoindole-2-carboxamides as a lipophilic chemotype of hetarene-anthraquinones potent against P-gp resistant tumor cells

IF 5.9 2区 医学 Q1 CHEMISTRY, MEDICINAL European Journal of Medicinal Chemistry Pub Date : 2025-01-05 Epub Date: 2024-10-30 DOI:10.1016/j.ejmech.2024.117013
Valeria A. Litvinova , Vladimir B. Tsvetkov , Yulia L. Volodina , Lyubov G. Dezhenkova , Alina A. Markova , Minh Tuan Nguyen , Alexander S. Tikhomirov , Andrey E. Shchekotikhin
{"title":"Naphthoindole-2-carboxamides as a lipophilic chemotype of hetarene-anthraquinones potent against P-gp resistant tumor cells","authors":"Valeria A. Litvinova ,&nbsp;Vladimir B. Tsvetkov ,&nbsp;Yulia L. Volodina ,&nbsp;Lyubov G. Dezhenkova ,&nbsp;Alina A. Markova ,&nbsp;Minh Tuan Nguyen ,&nbsp;Alexander S. Tikhomirov ,&nbsp;Andrey E. Shchekotikhin","doi":"10.1016/j.ejmech.2024.117013","DOIUrl":null,"url":null,"abstract":"<div><div>The acquisition of multidrug resistance (MDR) to chemotherapy is a major obstacle to successful cancer treatment. Aiming to improve the potency of anthraquinone-derived antitumor compounds against MDR cancer cells, we employed a rational design approach to develop new heteroarene-fused anthraquinones. Shifting the carboxamide group in the naphtho[2,3-<em>f</em>]indole scaffold from the 3-position to 2 increased the lipophilicity and P-glycoprotein (P-gp) binding of the derivatives, potentially enhancing their ability to circumvent P-gp-mediated MDR. To validate the computations, we developed a scheme for heterocyclization into esters of naphtho[2,3-<em>f</em>]indole-2-carboxylic acid, based on the 5-<em>endo</em>-dig cyclization of 2-alkynyl-3-amino-1,4-dimethoxyanthraquinone under mild basic conditions using tetra-<em>n</em>-butylammonium fluoride (TBAF). The synthesized naphthoindole-2-carboxamides, particularly compound <strong>1a</strong> bearing (<em>S</em>)-3-aminopyrrolidine in the carboxamide fragment, demonstrated the highest antiproliferative activity. Most importantly, <strong>1a</strong> suppressed the growth of the P-gp-positive K562/4 leukemia tumor cell line (resistance index = 2.4), while its 3-isomer <strong>LCTA-2640</strong> and <strong>Dox</strong> did not (RI = 125 and 140, respectively). Studies of intracellular uptake and distribution showed that <strong>1a</strong>, unlike its 3-substituted isomer, effectively accumulated in resistant tumor cells, confirming the correlation between <em>in silico</em> and experimental data. The lead compound <strong>1a</strong> interacts with DNA duplex and inhibits topoisomerase 1 but does not induce oxidative stress. Treatment with <strong>1a</strong> increases the population of apoptotic cells in both K562 and K562/4 sublines, regardless of the cell cycle phase. Taken together, this work provides an interesting example of how a little modification in chemical structure can lead to striking differences in antitumor properties. In conclusion, we have identified a potent class of compounds that offer distinct advantages in combating resistant tumor cells.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"281 ","pages":"Article 117013"},"PeriodicalIF":5.9000,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S022352342400895X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

The acquisition of multidrug resistance (MDR) to chemotherapy is a major obstacle to successful cancer treatment. Aiming to improve the potency of anthraquinone-derived antitumor compounds against MDR cancer cells, we employed a rational design approach to develop new heteroarene-fused anthraquinones. Shifting the carboxamide group in the naphtho[2,3-f]indole scaffold from the 3-position to 2 increased the lipophilicity and P-glycoprotein (P-gp) binding of the derivatives, potentially enhancing their ability to circumvent P-gp-mediated MDR. To validate the computations, we developed a scheme for heterocyclization into esters of naphtho[2,3-f]indole-2-carboxylic acid, based on the 5-endo-dig cyclization of 2-alkynyl-3-amino-1,4-dimethoxyanthraquinone under mild basic conditions using tetra-n-butylammonium fluoride (TBAF). The synthesized naphthoindole-2-carboxamides, particularly compound 1a bearing (S)-3-aminopyrrolidine in the carboxamide fragment, demonstrated the highest antiproliferative activity. Most importantly, 1a suppressed the growth of the P-gp-positive K562/4 leukemia tumor cell line (resistance index = 2.4), while its 3-isomer LCTA-2640 and Dox did not (RI = 125 and 140, respectively). Studies of intracellular uptake and distribution showed that 1a, unlike its 3-substituted isomer, effectively accumulated in resistant tumor cells, confirming the correlation between in silico and experimental data. The lead compound 1a interacts with DNA duplex and inhibits topoisomerase 1 but does not induce oxidative stress. Treatment with 1a increases the population of apoptotic cells in both K562 and K562/4 sublines, regardless of the cell cycle phase. Taken together, this work provides an interesting example of how a little modification in chemical structure can lead to striking differences in antitumor properties. In conclusion, we have identified a potent class of compounds that offer distinct advantages in combating resistant tumor cells.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
萘吲哚-2-羧酰胺作为一种亲脂型 Hetarene-Anthraquinones 化合物,对具有 P-gp 抗性的肿瘤细胞有效
对化疗产生多药耐药性(MDR)是成功治疗癌症的一大障碍。为了提高蒽醌类抗肿瘤化合物对 MDR 癌细胞的药效,我们采用合理的设计方法开发了新的杂芳烃融合蒽醌类化合物。将萘并[2,3-f]吲哚支架中的羧酰胺基团从 3 位移到 2 位,增加了衍生物的亲脂性和 P-glycoprotein (P-gp) 结合力,从而增强了它们规避 P-gp 介导的 MDR 的能力。为了验证计算结果,我们根据 2-炔基-3-氨基-1,4-二甲氧基蒽醌在温和碱性条件下使用四正丁基氟化铵 (TBAF) 进行 5-endo-dig 环化反应的结果,开发了一种杂环化为萘并[2,3-f]吲哚-2-羧酸酯的方案。合成的萘吲哚-2-羧酰胺类化合物,特别是羧酰胺片段中含有 (S)-3- 氨基吡咯烷的化合物 1a,显示出最高的抗增殖活性。最重要的是,1a 能抑制 P-gp 阳性的 K562/4 白血病肿瘤细胞系的生长(抗性指数 = 2.4),而其 3-异构体 LCTA-2640 和 Dox 则不能(抗性指数分别为 125 和 140)。对细胞内摄取和分布的研究表明,与 3-取代异构体不同,1a 能有效地在耐药性肿瘤细胞内积累,这证实了硅学数据与实验数据之间的相关性。先导化合物 1a 与 DNA 双链相互作用,抑制拓扑异构酶 1,但不会诱发氧化应激。用 1a 处理会增加 K562 和 K562/4 亚系的凋亡细胞数量,与细胞周期阶段无关。综上所述,这项工作提供了一个有趣的例子,说明化学结构上的微小变化如何导致抗肿瘤特性的显著差异。总之,我们发现了一类强效化合物,它们在抗击耐药性肿瘤细胞方面具有独特的优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
期刊最新文献
Design and optimization of potent, selective, and peripherally acting JNK3 inhibitors for chronic kidney disease Novel staurosporine-type indolocarbazole glycoalkaloids as potent and selective FLT3-ITD inhibitors for acute myeloid leukemia Targeting Staphylococcus aureus with potent de novo-designed proline-core short antimicrobial lipopeptides Who's who in the field of combretastatin A4 analogues: ? Mitochondria-targeted engineered peptide promotes myogenesis, mitigates fibrosis, and reduces inflammation in duchenne muscular dystrophy by suppressing mitoROS-mediated NF-κB activation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1